{
  "symbol": "AMGN",
  "year": 2025,
  "period": "Q1",
  "curated_text": "Symbol: AMGN. Year: 2025. Period: Q1. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Litigation Amgen Inc., Accord Healthcare, Inc., Intas Pharmaceuticals, Ltd.\u2019s, the U.S. District Court, a Consent Judgment and Injunction, Amgen Inc., Shanghai Henlius Biotech Inc., al, Amgen Manufacturing Limited LLC, Shanghai Henlius Biologics Co., Ltd, Organon & Co., the Shanghai Henlius, Organon Defendants, FDA, BLA, Amgen, Asserted, the New Jersey District Court, Denosumab Patent Litigation, Hikma Pharmaceuticals USA Inc., District Court, Gedeon, Gedeon Richter USA, Inc., Biocon Biologics, Inc., Biocon Biologics UK Limited, Biocon Biologics Limited, Biocon, the Massachusetts District Court, Biocon\u2019s, the Judicial Panel on Multidistrict Litigation, Conditional Order, Regeneron, California Central District Court, the \u2019099 Patent, the California Central District Court, Regeneron Pharmaceuticals, Inc., Delaware District Court, California\u2019s Unfair Practices Act, Sandoz Inc., Sandoz, U.S. Tax Litigation, Related Matters Amgen Inc. & Subsidiaries, IRS, Company, the U.S. Tax Court, Southern District Court, Shareholder Derivative Actions, the Delaware Court of Chancery, the Southern District Court, DM Cohen, Inc., Cheri Clearwater, the Delaware District Court, ChemoCentryx, The U.S. District Court, RA Capital Healthcare Fund, ANALYSIS OF FINANCIAL CONDITION, MD&A, SEC, EPS. Context excerpt: Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patents-in-suit are valid, enforceable and infringed and enjoining Accord from making, using, selling or offering for sale or importing its denosumab biosimilar products into the United States until the injunction expires on October 1, 2025. The confidential settlement allows Accord to launch its denosumab biosimilar products in the United States as early as October 1, 2025, subject to regulatory approval. Amgen Inc. et al. v. Shanghai Henlius Biotech Inc. et al. On June 25, 2025, Amgen Inc. and Amgen",
  "competition_summary": [
    {
      "competitor": "Litigation Amgen Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Accord Healthcare, Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Intas Pharmaceuticals, Ltd.\u2019s",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the U.S. District Court",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "a Consent Judgment and Injunction",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Amgen Inc.",
      "mentions": 6,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Shanghai Henlius Biotech Inc.",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "al",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Amgen Manufacturing Limited LLC",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Shanghai Henlius Biologics Co., Ltd",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Organon & Co.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the Shanghai Henlius",
      "mentions": 5,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Organon Defendants",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "FDA",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "BLA",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Amgen",
      "mentions": 22,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Asserted",
      "mentions": 5,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the New Jersey District Court",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Denosumab Patent Litigation",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Hikma Pharmaceuticals USA Inc.",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "District Court",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Gedeon",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Gedeon Richter USA, Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Biocon Biologics, Inc.",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Biocon Biologics UK Limited",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Biocon Biologics Limited",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Biocon",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the Massachusetts District Court",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Biocon\u2019s",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the Judicial Panel on Multidistrict Litigation",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Conditional Order",
      "mentions": 2,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Regeneron",
      "mentions": 4,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "California Central District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the \u2019099 Patent",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the California Central District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Regeneron Pharmaceuticals, Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Delaware District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "California\u2019s Unfair Practices Act",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Sandoz Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Sandoz",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "U.S. Tax Litigation",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Related Matters Amgen Inc. & Subsidiaries",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "IRS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Company",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the U.S. Tax Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Southern District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Shareholder Derivative Actions",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the Delaware Court of Chancery",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the Southern District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "DM Cohen, Inc.",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "Cheri Clearwater",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "the Delaware District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "ChemoCentryx",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "The U.S. District Court",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "RA Capital Healthcare Fund",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "ANALYSIS OF FINANCIAL CONDITION",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "MD&A",
      "mentions": 3,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "SEC",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    },
    {
      "competitor": "EPS",
      "mentions": 1,
      "context": "Competition and Innovation Act (BPCIA) Litigation Amgen Inc. et al. v. Accord et al. The parties entered into a confidential settlement agreement that resolves the patent litigation related to Accord Biopharma, Inc., Accord Healthcare, Inc. and Intas Pharmaceuticals, Ltd.\u2019s (collectively, Accord) denosumab biosimilar products. Accordingly, the U.S. District Court for the District of New Jersey (New Jersey District Court) entered a Consent Judgment and Injunction on July 16, 2025, that the patent"
    }
  ]
}